<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-X2ZJ2JJ9</identifier><date>2022</date><creator>Štrukelj, Borut</creator><relation>documents/doc/X/URN_NBN_SI_doc-X2ZJ2JJ9_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-X2ZJ2JJ9_001.txt</relation><format format_type="issue">2</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 137-140</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">108483075</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-X2ZJ2JJ9</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Holesterol</subject><subject language_type_id="slv">inklisiran</subject><subject language_type_id="slv">LDL-holesterol</subject><subject language_type_id="slv">monoklonska protitelesa</subject><subject language_type_id="slv">zaviralci PCSK-9</subject><title>Novel treatment approaches against elevated levels of cholesterol</title><title>Novosti pri zdravljenju povišanega holesterola</title></Record>